0 150

Cited 0 times in

Phase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

DC Field Value Language
dc.date.accessioned2023-06-02T01:05:59Z-
dc.date.available2023-06-02T01:05:59Z-
dc.date.issued2022-05-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/194652-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfANNALS OF ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titlePhase III study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorV.C. Dieras-
dc.contributor.googleauthorM. Martin Jimenez-
dc.contributor.googleauthorC.C.M. O'Sullivan-
dc.contributor.googleauthorJ. Sohn-
dc.contributor.googleauthorK. Tryfonidis-
dc.contributor.googleauthorL. Santarpia-
dc.contributor.googleauthorS. Yang-
dc.contributor.googleauthorE.P. Hamilton-
dc.identifier.doi10.1016/j.annonc.2022.03.226-
dc.relation.journalcodeJ00171-
dc.identifier.eissn1569-8041-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753422006056-
dc.citation.volume33-
dc.citation.numberSupplement 3-
dc.citation.startPageS222-
dc.identifier.bibliographicCitationANNALS OF ONCOLOGY, Vol.33(Supplement 3) : S222, 2022-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.